In today’s day and age the quest for medical perfection plays a role in all of our daily lives from many aspects. As part of this quest for extended life professionals within the medical field still record an annual Cancer Fatality rate of 577,190 people on average in the U.S alone. The way in which cancer spreads through the body in most cases makes it fairly hard to confront with what are known as standard treatment practices.
With this in mind the daily search for a perfect treatment continues as we speak. The United States is by far the leader within the healthcare spending global arena and there lies great opportunities for significant financial benefits when a strategic investment stance is taken within market. Based on this opportunity there is no single factor that can dictate success or potential failure more than timing. We carry this key element with us through many of our investment decisions on a daily basis to ensure success. After conducting significant due diligence and a perception of value based on short term potential future events we have chosen to present to you a company which appears to be on the precipice of what could be a time of change for the better. Medifocus inc. Is a medical device company that currently owns a patent within the microwave focusing technology segment of the cancer treatment arena. The technology is referred to as adaptive phased array system which has the unique ability to precisely target and concentrates microwave energy on cancer tumors without damaging the healthy tissue that surrounds the effected tissue. When this is used in conjunction with chemotherapy or radiation breast tumor shrinkage of an additional 50% has been witnessed in patients.
The Company has received Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) and Investigational Testing Authorization (ITA) from Health Canada’s Medical Device Bureau (MDB) for its pivotal phase III trial with the Microfocus APA 1000 Breast Thermotherapy System for the treatment of breast cancer. A total of 238 patients will be entered into the phase III study in the United States and Canada. Information regarding the Medifocus clinical trial is available on the U.S. National Institutes of Health ClinicalTrials.gov web site at http://www.clinicaltrials.gov/ct2/show/NCT01204801?term=medifocus&rank=1
Based on the fact that the current share structure of MDFZF is below 100m shares with a market cap of roughly 14 million we feel as if Medifocus could turn profitable results from its current price point of .145 cents per share. Medifocus inc has stated that 120 million dollars in annual revenues will be produced off of just 200 adaptive phase array systems placed nationwide. To ensure that a strategically adapt management team is in place it will enlighten you to the fact that current Management has successfully commercialized “Prolieve”, a heat treatment system for BPH and sold Prolieve to Boston Scientific Corp for over $100 M in return.
To ensure that a strategically adapt management team is in place it will enlighten you to learn that the current Management team has successfully commercialized “Prolieve”, a heat treatment system for BPH and sold Prolieve to Boston Scientific Corp for over $100 M in returns. In a recent release the company made public to the investment community that they would be showing a revenue for the first time in its history in this current quarter. With so much natural expansion within the current bio segment taking place and these well timed positive factors we feel as if the current share price could have a potentially positive movement for MDFZF investors in the short and mid-term.
Market Data 
Markets 
AI
